These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10863533)

  • 21. Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase.
    Vindis C; Séguélas MH; Lanier S; Parini A; Cambon C
    Kidney Int; 2001 Jan; 59(1):76-86. PubMed ID: 11135060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoamine oxidase and mitochondrial respiration.
    Cohen G; Kesler N
    J Neurochem; 1999 Dec; 73(6):2310-5. PubMed ID: 10582588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
    Seif-El-Nasr M; Atia AS; Abdelsalam RM
    Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
    Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
    J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoamine oxidase inhibition prevents mitochondrial dysfunction and apoptosis in myoblasts from patients with collagen VI myopathies.
    Sorato E; Menazza S; Zulian A; Sabatelli P; Gualandi F; Merlini L; Bonaldo P; Canton M; Bernardi P; Di Lisa F
    Free Radic Biol Med; 2014 Oct; 75():40-7. PubMed ID: 25017965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
    Mazumder MK; Paul R; Phukan BC; Dutta A; Chakrabarty J; Bhattacharya P; Borah A
    Med Hypotheses; 2018 Aug; 117():54-58. PubMed ID: 30077198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondrial damage by nitric oxide is potentiated by dopamine in PC12 cells.
    Antunes F; Han D; Rettori D; Cadenas E
    Biochim Biophys Acta; 2002 Dec; 1556(2-3):233-8. PubMed ID: 12460681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of selective monoamine oxidase inhibitors on rat brain mitochondrial monoamine oxidase during hyperbaric oxygenation.
    Goroshinskaya IA; Bronovizkaya ZG; Gorkin VZ
    Commun Psychopharmacol; 1977; 1(1):39-47. PubMed ID: 606471
    [No Abstract]   [Full Text] [Related]  

  • 29. [Changes induced by ethanol in monoamine oxidase activity in the rat's brain mitochondria: MAO-DA and MAO-NA].
    Renis M; Giovine A; Bertolino A
    Acta Neurol (Napoli); 1974; 29(3):293-8. PubMed ID: 4422384
    [No Abstract]   [Full Text] [Related]  

  • 30. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoamine oxidase inactivation: from pathophysiology to therapeutics.
    Bortolato M; Chen K; Shih JC
    Adv Drug Deliv Rev; 2008; 60(13-14):1527-33. PubMed ID: 18652859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives on MAO-B in aging and neurological disease: where do we go from here?
    Kumar MJ; Andersen JK
    Mol Neurobiol; 2004 Aug; 30(1):77-89. PubMed ID: 15247489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular turnover numbers of different forms of mitochondrial monoamine oxidase in rat.
    Egashira T; Ekstedt B; Kinemuchi H; Wiberg A; Oreland L
    Med Biol; 1976 Aug; 54(4):272-7. PubMed ID: 957813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease.
    Shen XM; Li H; Dryhurst G
    J Neural Transm (Vienna); 2000; 107(8-9):959-78. PubMed ID: 11041275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
    Liu Z; Cai W; Lang M; Yan R; Li Z; Zhang G; Yu P; Wang Y; Sun Y; Zhang Z
    J Mol Neurosci; 2017 Apr; 61(4):498-510. PubMed ID: 28144826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson's disease.
    Kumar MJ; Nicholls DG; Andersen JK
    J Biol Chem; 2003 Nov; 278(47):46432-9. PubMed ID: 12963742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
    Cohen G
    J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.